Drugs / Bivalent Subtype C gp120/MF59 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02915016 | Dec 2016 → Aug 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent Subtype C gp120/MF59 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02915016 ↗ |
| Modality | Vaccine | “Bivalent Subtype C gp120/MF59 vaccine” NCT02915016 ↗ |
| Route | Intramuscular | “administered by IM injection to the right deltoid” NCT02915016 ↗ |